Mindset Pharma Reports Fiscal Year 2021 Financial Results and Provides Corporate Update - Seite 2

Advanced First Lead Drug Candidate Toward Clinical Trials: Selected its first lead clinical candidate, MSP-1014, a differentiated psilocybin-based analog, to move forward into investigational new drug (IND)-enabling studies.

Developed First-in-Class Benchmarking: Under the Cooperative Psychedelics Evaluation Platform (“COPE”) program, Mindset and its partner, InterVivo Solutions, continue to develop first-in-class benchmarking data across first-generation psychedelic drugs.

Identified Technology Platform: Preclinical data generated across the four families of novel chemical entities resulted in the identification of a platform technology that enhances effect size and improves safety profiles of psychedelic drugs. A provisional patent application was filed in May of 2022.

Enhanced Leadership and Advisory Teams: Appointed Dr. Malik Slassi as Senior Vice President of Innovation, Mr. Ian Dean as Director of Preclinical Development, and Drs. Michael Rogawski, Guy Higgins, Joseph Gabriele and Ishrat Husain to its Scientific Advisory Board (SAB).

• Dr. Slassi is a scientific co-founder and an originating member of Mindset's SAB and is the architect of the Company's intellectual property portfolio of novel and differentiated psychedelic drug families, along with the its patent pending psilocybin synthesis process.
• Mr. Dean is a seasoned toxicologist and pharmacology professional with over 40 years of intensive expertise in drug development.
• Dr. Rogawski is Professor of Neurology and Pharmacology at the University of California, Davis School of Medicine. Serves as lead of the University of California Drug Discovery Consortium and Member of board of directors of the American Epilepsy Society.
• Dr. Higgins brings more than three decades of expertise in the pharmaceutical industry as a drug developer and is a world renowned psychopharmacologist with greater than 180 peer reviewed publications in behavioural neuroscience.
• Dr. Gabriele is a molecular pharmacologist with extensive experience in product formulation and commercialization.
• Dr. Husain is a leading researcher in the neurobiology of depression and bipolar disorder, currently conducting clinical trials of emerging treatments for these conditions.